How Should an IBD Prevention Trial Be Designed?
Prevention trials in IBD hold promise but require careful design informed by experiences from other IMIDs. Central to this effort are the development of validated predictive tools, ethically appropriate interventions, and international collaboration to assemble well-powered at-risk cohorts.
Authors
- Jean‐Frédéric Colombel (ORCID: https://orcid.org/0000-0001-6472-249X)
- Ryan C. Ungaro (ORCID: https://orcid.org/0000-0001-8687-3758)
- Vipul Jairath (ORCID: https://orcid.org/0000-0002-1092-0033)
- Brian G. Feagan (ORCID: https://orcid.org/0000-0002-6914-3822)
- Geert D’Haens (ORCID: https://orcid.org/0000-0003-2784-4046)
- Rogier Goetgebuer (ORCID: https://orcid.org/0000-0003-1349-9501)
Institutions
- Western University (CA)
- Amsterdam University Medical Centers (NL)
- University of Amsterdam (NL)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Inflammatory Bowel Diseases
- Published
- 2025-09-24
- DOI
- https://doi.org/10.1093/ibd/izaf212
- Primary Topic
- Celiac Disease Research and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00